- Source : Press Release
- Date : 2020-12-03
- Event type : Phase 2
- Companies : Roche
Genexine, Roche to Research Combination Treatment for Cancer
Genexine and Roche will cooperate in using combination therapy to treat recurrent glioblastoma multiforme. (Genexine)
Genexine said Wednesday they have signed an agreement with Roche to start the research for a combination treatment using GX-I7, Genexine's immunotherapy candidate, and Roche's Avastin.
The two companies will evaluate the efficacy and safety of the combination treatment for patients with recurrent glioblastoma multiforme (rGBM).
“There is great interest in the collaboration between the two companies,” Genexine said in a news release. “We recently confirmed that by presenting the significant results of the GX-17-Avastin combo therapy at the KAI International Meeting 2020.”
Glioblastoma is one of the most common and fatal types of malignant brain tumors, accounting for about 12 percent of all brain tumors. The survival period without treatment is less than four to six months, and the average survival period, even with the combination of surgery and radiation therapy, is less than 12 months.
Among them, rGBM is known as a brain tumor with the worst prognosis.
“The combined administration of GX-I7 is expanding not only to immune checkpoint inhibitors, but also to various anticancer drugs, including targeted anticancer drugs, chemotherapy drugs, cell therapy drugs, and anticancer vaccines,” Genexine CEO Sung Young-chul said. “Through this clinical trial, the company expects that the combination of GX-I7 and Avastin will become a new treatment option for rGBM.”